Medical Training Application Service This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
NuSmile NeoMTA ® Launches in Canada
Breakthrough material is the only affordable MTA specifically optimized for pediatric dentistryHOUSTON, TEXAS, April 6, 2017 —NuSmile Ltd., the worldwide leader in pediatric esthetic restorative dentistry, announced today that its NuSmile NeoMTA is now available in Canada.NuSmile NeoMTA is the first and only affordable MTA specifically optimized for pediatric dentistry. The ideal treatment for pulpotomies, direct and indirect pulp capping, and apexification, it is quickly wash- out resistant, non-staining and has excellent handling properties. NuSmile NeoMTA is also bioactive and non-toxic, delivering peace of mind t...
Source: Dental Technology Blog - April 14, 2017 Category: Dentistry Source Type: news
Developing Guidance Tools for Biological Sample Sharing in Public Health Emergencies
World Health Organization. 12/20/2016 This resource summarizes an initial consultation held on December 16, 2016, on building capacity for material transfer agreements (MTAs) in public health emergencies. These agreements govern the transfer of research materials between two organizations or countries, and define the rights of the provider and the recipient. The meeting brought together experts to consider how best to promote the use of MTAs in low-income countries, where epidemics are more likely to occur and health system capacity is limited. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - January 28, 2017 Category: Global & Universal Authors: The U.S. National Library of Medicine Source Type: news
Georgia Regents University Launches Immunotherapy Clinical Trial
The Georgia Regents University Cancer Center, a national leader in immunotherapy research, has opened its first clinical trial for mesothelioma patients. The Phase 2 trial is open to patients with unresectable peritoneal or pleural mesothelioma, providing a promising new treatment option for this rare and aggressive cancer. Immunotherapy involves triggering the body's own immune system to identify and destroy the cancer cells without harming the healthy ones. This multicenter trial will study the drug tremelimumab, which has shown an ability to stimulate the immune system and attack tumors. It already has shown potential ...
Source: Asbestos and Mesothelioma News - September 22, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news